






Supplementary Fig. 1.



Supplementary Fig. 2.



Supplementary Fig. 3.

Supplementary Table I. Patient baseline demographics and clinical characteristics of RA patients treated with abatacept

	Responder	Non-responder	<i>p</i>
Sex (M/F)	0/5	1/9	
Age (years)	69.6 ± 13.6	64.1 ± 18.4	0.5809
Disease duration (months)	168 ± 124.9	232 ± 221	0.7128
Prednisolone dose (mg/day) (% of use)	5.0 (20%)	3.0 (10%)	0.5346
Methotrexate dose (mg/week) (% of use)	12.0 ± 4.3 (80%)	12.3 ± 2.9 (80%)	0.9311
Other medication	Salazosulfapyridine	Salazosulfapyridine Tacrolimus	
Tender joint count (28)	7.0 ± 5.1	5.5 ± 2.5	0.7547
Swollen joint count (28)	3.6 ± 1.8	4.7 ± 2.9	0.5785
CRP (mg/dl)	0.9 ± 0.5	1.8 ± 1.9	0.6676
RF (IU/ml) (% of positivity)	64 ± 71 (80%)	181.2 ± 374.8 (80%)	0.8065
Anti-CCP antibody (% of positivity)	(80%)	(80%)	
MMP-3	156 ± 169	157.2 ± 103.6	0.5403
IgG (mg/dl)	1583 ± 259	1470.7 ± 370.4	0.2203
DAS28 (ESR)	3.8 ± 1.2	5.5 ± 1.3	0.0275
SDAI	13.1 ± 4.6	23.9 ± 10.4	0.0275
HAQ	0.8 ± 0.7	1.5 ± 0.9	0.2404